Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs.
Biomed’s team has discovered a new family of drugs for the treatment and prevention of Alzheimer’s disease. Today there are more than 6 million people in the US and 50 million people around the world have suffered from Alzheimer’s disease.
Biomed Industries, Inc. is the holding company of Biomed Pharmaceuticals, Inc, NeuroActiva, Inc., and BiomedAI, LLC.
Biomed Pharmaceuticals™ Inc. was the developer of Artemether, which was approved by the FDA along with lumefantrine for the treatment of malaria. A Phase 3 trials of Artemether is being tested to treat Covid-19.
NeuroActiva™is the developer of Traneurocine (NA-831) which is ready for Phase 3 clinical trials for the prevention and treatment of Alzheimer's disease and other neurodegenerative diseases. (http://www.neuroactiva.com)
BiomedAI focuses on the application of Artificial intelligence (AI) using computer mimicking “intellectual processes characteristic of humans” to accelerate our drug discovery, drug development and patients screening programs in clinical trials.
The management team is led by Lloyd L. Tran, the company Chairman. Lloyd was a research scientist, with 25-year experience in drug discovery working for some major pharmaceutical companies including Monsanto and Pfizer.
Lloyd was the drug developer of Artemether for the treatment of malaria in early 1990’s in collaboration with a Chinese research team. He coordinated the clinical trials of Artemether gel capsule with World Health Organization (WHO) and Walter Reed Army Institute of Research (WRAIR) that lead to its approval in over 80 countries worldwide, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration.
After the success of Artemether, Lloyd focused on neurodegenerative diseases when his father developed symptoms of Alzheimer’s disease. He filed his first patent application in 2001 on neurogenesis for Alzheimer’s disease. His latest patent was issued in August 2021 on the “Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders”.
It has been discovered that in Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive impairment. Our drug, NA-831 facilitates neurogenesis restoring memory loss and improve cognitive functions.
The recent controversy approval of Biogen’s Aducanumab by the FDA in early June 2021 has opened great opportunities for Biomed to offer our new drug treatment methodology for Alzheimer’s disease.
While Aducanumab focuses on the removal of amyloid beta on the brain, Biomed’s method focuses on protecting the brain (neuroprotection) and facilitating the regeneration of new neurons (neurogenesis).
The approval of Aducanumab (Aduhelm) is based on a surrogate biomarker which is a small reduction of amyloid beta, which does not correspond to any significant improvement of cognitive functions. In addition, more than 40% of subjects in the two phase 3 trials of Aducanumab developed serious side effects caused by Amyloid Related Imaging Abnormalities (ARIA).
NA-831 which is based on mechanism of action of neurogenesis, directly related to restoring memory loss and improvement of cogntive improvement. The Phase 2A clinical data of NA-831 has shown a proof of safety and efficacy for patients with mild and moderate Alzheimer's disease. We plan to conduct a Phase 2B and Phase 3 for the treatment and prevention of Alzheimer's disease.
NeuroActiva has conducted a Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and Mild and Moderate Alzheimer’s Disease.
NA-831 was well-tolerated with no adverse events or concerning safety signals. In addition, there was a significant improvement in the memory test performance for the Alzheimer’s patients in the study who were administered NA-831 compared to placebo.
NA-831 showed a significant improvement for patients with mild and moderate AD with the ADAS-Cog score changed of an average of 4.1 as compared to the placebo after 24 weeks of treatment . The Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) showed 82.1% patients improved.
The clinical results of the Phase 1 and Phase 2 of NA-831 have been presented at various international conference including: the Alzheimer Association International Conference (AAIC) - July 25, 2018 in Chicago, Alzheimer Society International Congress (ASIC), February 18-21, 2021 in San Francisco, AAIC, July 17, 2019 in Los Angeles, and the Clinical Trials on Alzheimer's Disease International Conference (CTAD), December 4-7, 2019 in San Diego
The Phase 3 clinical trials of NA-831 has been scheduled in 2022 to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
NA-704™ exhibits neuroprotection and neurogenesis, which has been demonstrated as a strong candidate for treatment of Alzheimer’s disease and other neurological disorders. NA-704 is to be administered intravenously once a week, per prescription of a qualified physician.
For more information about our neurological drugs for the prophylaxis and treatment of Alzheimer's disease, please visit the Alzheimer's Drug Therapy webpage.
The MICROS™ Infusion System has been approved by the United Stated Food and Drug Administration (FDA) for marketing in the USA.
The MICROS Infusion System is a disposable infusion system designed for the intravenous administration of injectable drugs. There are more than 100 injectable drugs can be used with the MICROS for treatment of infectious diseases, cancer chemotherapy and cardiovascular diseases and neurological diseases.
The MICROS can be prefilled with NA-704 for controlled release of the injectable medication for treatment of Alzheimer's disease and Multiple Sclerosis.
MICROS is a controlled released infusion system that can be prefilled with a customized dosage of NA-704 to be available as a premixed and ready to use package.
The NA-704/MICROS infusion system offers an accurate intravenous dosage and is ready to be administered to the patient in a convenient and comfortable setting at home for Alzheimer patients.
For more information about the MICROS™ Infusion System, please visit the MICROS webpage.
For further information about our products, please contact us by completing an Online Contact Form. Thank you.
Learn more
The hippocampus is essential for learning and memory formation and one of the first brain regions affected in the development of Alzheimer’s disease (AD). In the hippocampus, new neurons are generated throughout life via a process called adult hippocampal neurogenesis (AHN).
In mild cognitive impairment (MCI) and mild to moderate AD (early AD), AHN is reduced suggesting that AHN impairment compromises hippocampal function. Accordingly, augmenting AHN could help prevent or slow cognitive decline in MCI and early AD.
NA-831 restores neurogenesis by activating synaptic AMPA receptors, and increases the expression of BDNF (brain derived neurotrophic factor). BDNF is crucial in synaptic plasticity, learning and memory formation in the hippocampus.
Traneuroci™ or NA-831 provides neuroprotection and catalyzing the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed.
Learn more
In Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive disorders. NA-831 facilitates neurogenesis restoring memory loss and improve cognitive functions.
Learn more
Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also conduct Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19
Learn more
Vineurocin (NA-704) is an injectable drug, to regenerate new neurons, and reducting of muscular spasticity, a strong candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.
Learn more
Combination therapy of NA-831 and an antiviral drugs such as Atazanavir, Remdesivir (Gilead Sciences) and anti-inflammatory such as Dexaneurosone and Ivermectin can enhance the effectiveness of the treatment of Covid-19.
Learn more
